Dr. Taylor on Treatments in Development for Endometrial Cancer

Alexandra Taylor, MD
Published: Thursday, Jan 04, 2018



Alexandra Taylor, MD, consultant, clinical oncology, The Royal Marsden Hospital, discusses treatments in development for patients with endometrial cancer.

There is a better knowledge of the molecular changes that can guide physicians toward specific pathways where targeted agents may have activity, explain Taylor.

According to Taylor, there are many phase II studies investigating single-agent targeted therapies, particularly with the mTOR inhibitors targeting the PI3-kinase pathway, as well as the antiangiogenic agents.
 


Alexandra Taylor, MD, consultant, clinical oncology, The Royal Marsden Hospital, discusses treatments in development for patients with endometrial cancer.

There is a better knowledge of the molecular changes that can guide physicians toward specific pathways where targeted agents may have activity, explain Taylor.

According to Taylor, there are many phase II studies investigating single-agent targeted therapies, particularly with the mTOR inhibitors targeting the PI3-kinase pathway, as well as the antiangiogenic agents.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x